Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Summary

The main purpose of this study is to assess safety and reactogenicity of the 3 vaccine regimens.

Timeline

Start

2018-09-27

Primary completion

2020-10-15

Completion

2020-10-15

Outcome

Outcome not reported

Stopped: “Low enrolment and increasing COVID restrictions, following an earlier enrolment pause in April made it clear that completion of the study would not be feasible”

Drugs

Indications